Friday, February 25, 2011 1:10:48 AM
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2010.
Fourth-quarter reported revenues were $533.7 million, up 7.8% compared to $495.1 million reported for the fourth quarter of 2009. On a currency-neutral basis, quarterly revenues increased 9.9% compared to the same period last year. This increase was the result of organic growth across Bio-Rad's two main areas, Life Science and Clinical Diagnostics as well as revenue of $15.3 million resulting from the acquisition of certain diagnostics businesses of Biotest AG, which were added to the Company's portfolio in the first quarter of 2010. Excluding the revenue from the Biotest acquisition, fourth-quarter revenues were up 6.7% on a currency neutral basis. Fourth-quarter gross margin increased to 56.2% compared to 54.2% during the same quarter last year.
Net income attributable to Bio-Rad for the fourth quarter of 2010 was $67.9 million, or $2.41 per share on a fully diluted basis compared to $1.35 per share, during the same period last year. In December, the Company refinanced a portion of its long-term debt issuing $425 million of senior debt. Proceeds were used to retire $200 million of subordinated debt in December and, subsequent to year end, $225 million of subordinated debt. The effect of this transaction on pretax earnings for the fourth quarter of 2010 was $5.3 million, which is included in interest expense.
The tax provision for the fourth quarter was a benefit of $10.7 million. This extraordinary fourth-quarter provision benefit includes the repatriation of foreign earnings to the U.S. and the favorable impact of the extension of the U.S. Research and Experimentation tax credit. Without these two items, the fourth-quarter effective tax rate would have been approximately 25%.
For the full year, sales grew by 8.0% to $1,927.1 million compared to $1,784.2 million in 2009. Year over year, there was insignificant currency impact on sales growth. Full-year net income attributable to Bio-Rad was $185.5 million, or $6.59 per share on a fully diluted basis, compared to $144.6 million, or $5.20 per share, respectively, in 2009. Full-year gross margin increased to 56.6% compared to last year's figure of 56.0%.
"We are pleased by our performance during the fourth quarter and the entire year," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "In spite of a cautious business environment in the U.S. and Europe throughout 2010, we are encouraged by customer acceptance of several new products including our TC10™ automated cell counter and our IH-1000 automated blood typing platform. Although continued economic pressure from European markets is predicted, we expect 2011 to be another year of progress for Bio-Rad."
Life Science
The Life Science segment net sales for the fourth quarter were $192.9 million, up 1.0% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 2.2%. Full-year reported revenues for the Life Science segment were $648.1 million, up 2.6% over the prior year, or an increase of 2.2% on a currency-neutral basis. European sales continued to lag in the fourth quarter as a result of weak economic conditions facing government-funded research. During the quarter, the Life Science segment benefited from sales of precast electrophoresis gels as well as its next generation PCR instruments, in particular, the CFX96™ real-time PCR detection system.
The TC10 automated cell counter also continued to gain rapid customer acceptance on a global basis. In November, Bio-Rad launched the Criterion® TGX Stain-Free™ precast electrophoresis gels which, when combined with Bio-Rad's Gel Doc™ EZ imager, provide researchers with the fastest protein separation and visualization available.
Clinical Diagnostics
The Clinical Diagnostics segment reported net sales of $336.5 million for the fourth quarter, up 12.0% compared to the same period in 2009. On a currency-neutral basis, net sales were up 14.7%. These results include additional revenue of $15.3 million from the diagnostics businesses of Biotest AG that were added to the Company's portfolio in the first quarter of 2010. Excluding revenue from the Biotest acquisition, net sales were up 9.3% on a currency-neutral basis compared to the same quarter last year. Full-year reported revenues for the Clinical Diagnostics segment were $1,265.3 million, an increase of 11.0% over the prior year. On a currency-neutral basis, full-year sales increased 11.3% compared to 2009 results. Excluding revenue from the Biotest acquisition, full-year sales increased 6.3% on a currency neutral basis. Performance in the Clinical Diagnostics segment during the fourth quarter was the result of growth across all product lines, most notably quality controls, blood typing, diabetes monitoring, as well as sales of the BioPlex 2200® system. During the fourth quarter, the Company announced FDA clearance and the U.S. launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. This novel marker has been shown to have superior diagnostic specificity.
2010 Full-Year Highlights
-- Full-year Company sales grew by 8.0% to $1,927.1 million.
-- Year-over-year net income was $185.5 million, or $6.59 per share on a
fully diluted basis, compared to $144.6 million, or $5.20 per share in
2009.
-- In January, Bio-Rad completed the purchase of certain diagnostics
businesses of Biotest AG including its diagnostics products in the
areas of blood transfusion testing, transplantation, and infectious
diseases.
-- Also, in January, Bio-Rad announced the launch of a new Anti-CCP test
for markets outside the U.S. for its BioPlex 2200 system for the early
detection of rheumatoid arthritis. After receiving FDA clearance later
in the year, the product was launched in the U.S.
-- In March, Bio-Rad announced the launch of the Mini-PROTEAN® TGX™
precast gels that provide researchers with the fastest running, long
shelf life precast gels for protein electrophoresis.
-- In May, Bio-Rad introduced the TC10 automated cell counter, which
accurately and reproducibly provides total mammalian cell counts in 30
seconds, eliminating the need for manually counting cells.
-- Also in May, the Clinical Diagnostics segment announced the launch of
the BioPlex® 2200 MMRV IgG kit (measles, mumps, rubella, and the
varicella-zoster virus) for use on the company's BioPlex 2200 system.
-- During the second quarter, Bio-Rad received notification from the FDA
that it could proceed with an Investigational New Drug Study for its
Dengue NS1 Ag microplate assay.
-- In June, Bio-Rad announced the launch of its IH-1000 blood screening
system for markets outside the U.S.
-- In July, Bio-Rad submitted Premarket Approval application to the FDA
for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme
immunoassay), offering early detection of HIV infections as well as
acute HIV infections.
-- In September, Bio-Rad announced the launch of the Gel Doc EZ imager,
the first gel documentation system that provides publication-quality
images and analysis in seconds.
-- In November, the Life Science segment launched Criterion TGX Stain-Free
precast gels which, when combined with Bio-Rad's Gel Doc EZ imager,
provide researchers with the fastest protein separation and
visualization available.
-- In December, Bio-Rad successfully issued $425 million of senior debt.
As a result of that transaction, the Company redeemed $200 million of
subordinated debt originally due in 2014. Subsequently, in January
2011, the Company redeemed $225 million of subordinated debt originally
due 2013...Much more at link below, Stockinvestor
http://ih.advfn.com/p.php?pid=nmona&article=46616267
Recent BIO News
- Dell, Palantir, and Erie Will Be Added to the S&P 500; Boeing Avoids Strike; Apple Event Takes Place Today • IH Market News • 09/09/2024 10:05:35 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference • Business Wire • 08/22/2024 08:30:00 PM
- Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer • Business Wire • 08/20/2024 12:30:00 PM
- Bio-Rad Reports Second-Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:15:00 PM
- Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024 • Business Wire • 07/17/2024 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:37:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 05:42:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 09:50:32 PM
- Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group • Business Wire • 05/30/2024 01:00:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference • Business Wire • 05/23/2024 08:15:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/09/2024 08:30:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:38:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:26 PM
- Bio-Rad Reports First-Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:15:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM